# Feasibility Assessment: AD Pipeline Hypotheses
## Surviving Hypotheses After Critique
**H1 (Pipeline Distortion)** is an *observation*, not a therapeutic hypothesis. It survives as framing but offers no actionable target. Move to context-setting.
**H2, H3, and H4** remain viable with modifications. Below are targeted feasibility assessments.
---
## Hypothesis 2: Microglial Targets (TREM2, PLCG2, INPP5D)
### Druggability & Therapeutic Potential
| Target | Modality | Feasibility | Notes |
|--------|----------|-------------|-------|
| **TREM2** | Agonistic antibodies, small molecule activators | **Moderate-High** | Genetic validation is strong; BBB penetration is the primary barrier |
| **PLCG2** | Positive allosteric modulators | **Moderate** | P522R variant provides clear pharmacodynamic hypothesis; no CNS-penetrant leads yet |
| **INPP5D (SHIP1)** | Inhibitors (existing oncology compounds) | **Low-Moderate** | BBB penetration demonstrated in CNS oncology; systemic toxicity concerns |
**Realistic potential:** Modest disease modification by shifting microglia toward Aβ clearance phenotype. Monotherapy unlikely to match anti-amyloid efficacy; more plausible as combination component.
### Existing Compounds/Trials
- **TREM2 agonists:** No clinical-stage programs as of 2024. Preclinical: AL002 (Alector), but this was discontinued after Phase II failure in 2022. Slightly earlier-stage: antibodies in academic settings (University of California, Alzheimer's Research UK funded programs).
- **PLCG2 modulators:** No disclosed clinical programs. Fragment-based discovery has identified initial hit series.
- **INPP5D inhibitors:** Tenalisib (RBx-05959) in oncology trials; no AD-specific development.
### Development Cost & Timeline
- **Cost:** $200-400M to Phase II (BBB-permeable biologics/small molecules)
- **Timeline:** 7-10 years to Phase II completion
- **Major cost driver:** TREM2-targeting antibodies require IV delivery; blood-brain barrier penetration often requires active transport engineering
### Safety Concerns
- **TREM2:** Overactivation may dysregulate microglial homeostasis; theoretical risk of cytokine release or impaired surveillance
- **PLCG2:** Constitutive activity may promote inflammation; isoform selectivity critical
- **INPP5D:** SHIP1 inhibition in oncology shows GI toxicity, pneumonitis risk; CNS exposure may compound these
---
## Hypothesis 3: Mitochondrial & Proteostatic Mechanisms
### Druggability & Therapeutic Potential
| Target | Modality | Feasibility | Notes |
|--------|----------|-------------|-------|
| **NAD⁺ augmentation** | NR, NMN, nicotinamide riboside | **High** | Oral bioavailability established; BBB penetration moderate |
| **SIRT1/3 activators** | Small molecule activators | **Moderate** | Selective activation is difficult; resveratrol failed clinically |
| **Autophagy modulators** | mTOR inhibitors (rapamycin analogs), TFEB activators | **Moderate** | Non-selective mTOR inhibition has tolerability issues |
**Realistic potential:** Neuroprotective maintenance rather than disease modification. Best positioned as **preventive** or combinatorial strategy. NAD⁺ augmentation is the most translation-ready.
### Existing Compounds/Trials
- **NAD⁺ boosters:** Nicotinamide riboside (Tru NIAGEN) in multiple investigator-initiated AD trials; NMN in early human studies in Japan. No sponsor-initiated Phase II efficacy trials.
- **SIRT1 activators:** SRT2104 (葛兰素史克) completed Phase II in ulcerative colitis; no AD trials.
- **Autophagy modulation:** Rapamycin in aging trials; no AD-specific development despite strong preclinical data.
### Development Cost & Timeline
- **Cost:** $50-150M to Phase II for repurposed agents (NR, NMN); $300M+ for novel autophagy modulators
- **Timeline:** 4-6 years for NAD⁺ augmentation (using existing compounds); 8-12 years for selective SIRT1/3 activators
- **Advantage:** Existing tox profiles and human safety data accelerate development
### Safety Concerns
- **NAD⁺ augmentation:** Generally well-tolerated; theoretical concerns about overactivation of NAD⁺-consuming enzymes (PARPs, CD38) in cancer patients
- **SIRT1 activators:** Cardiovascular effects possible (SIRT1 affects eNOS); narrow therapeutic window
- **Autophagy modulators:** Immunosuppression risk (mTOR inhibitors); metabolic effects
---
## Hypothesis 4: Combinatorial & Preventive Trials
This is a **trial design hypothesis**, not a drug target. Assess feasibility of the proposed strategies:
### Combination Trials
**Feasibility: Moderate**
- Anti-amyloid + anti-inflammatory combinations are conceptually straightforward
- Regulatory pathway exists (parallel development) but requires two active compounds
- Example models: Cancer immunotherapy combinations; cardiovascular polypharmacy
**Barriers:**
- Two-company partnerships are difficult to negotiate
- Liability allocation for adverse events
- Dosing complexity (drug-drug interactions poorly studied in AD)
### Preventive Trials
**Feasibility: Low-Moder